CD137 (4-1BB) and T-Lymphocyte Exhaustion

Clin Cancer Res. 2024 Sep 13;30(18):3971-3973. doi: 10.1158/1078-0432.CCR-24-1568.

Abstract

CD137 (4-1BB) costimulation results in the potent activation of antitumor T lymphocytes and elicits antitumor efficacy that is synergistic with anti-PD(L)1 checkpoint inhibitors, especially when using bispecific constructs. Emerging experimental evidence indicates that 4-1BB ligation prevents and may revert T-cell exhaustion. See related article by Jeon et al., p. 4155.

MeSH terms

  • Animals
  • Humans
  • Immune Checkpoint Inhibitors / pharmacology
  • Immune Checkpoint Inhibitors / therapeutic use
  • Lymphocyte Activation / drug effects
  • Lymphocyte Activation / immunology
  • Neoplasms* / drug therapy
  • Neoplasms* / immunology
  • Neoplasms* / pathology
  • T-Cell Exhaustion
  • T-Lymphocytes* / immunology
  • Tumor Necrosis Factor Receptor Superfamily, Member 9* / immunology

Substances

  • Tumor Necrosis Factor Receptor Superfamily, Member 9
  • Immune Checkpoint Inhibitors
  • TNFRSF9 protein, human